Pemetrexed and cisplatin in patients with advanced gastric cancer

A Korean cancer study group multicenter phase II study

Yeul Hong Kim, Hyun Cheol Chung, Won Ki Kang, Sook Ryun Park, Chul Soo Kim, Tae Yue Kim, Sang Won Shin, Byung Joo Park, Soo Jin Cha, Yung Jue Bang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. Patients and methods: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. Results: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6-40.3%) and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2-4.4 months), and median overall survival was 6.6 months (95% CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles). Conclusion: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.

Original languageEnglish
Pages (from-to)263-270
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume62
Issue number2
DOIs
Publication statusPublished - 2008 Jul 1

Fingerprint

Pemetrexed
Cisplatin
Multicenter Studies
Stomach Neoplasms
Toxicity
Tumors
Folic Acid Antagonists
Neoplasms
Chemotherapy
Enzyme Inhibitors
Vitamin B 12
Folic Acid
Labels
Anorexia
Patient Safety
Neutropenia
Clinical Trials
Safety
Drug Therapy

Keywords

  • Advanced gastric cancer
  • Chemotherapy
  • Cisplatin
  • Pemetrexed
  • Phase II trial

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Pemetrexed and cisplatin in patients with advanced gastric cancer : A Korean cancer study group multicenter phase II study. / Kim, Yeul Hong; Chung, Hyun Cheol; Kang, Won Ki; Park, Sook Ryun; Kim, Chul Soo; Kim, Tae Yue; Shin, Sang Won; Park, Byung Joo; Cha, Soo Jin; Bang, Yung Jue.

In: Cancer Chemotherapy and Pharmacology, Vol. 62, No. 2, 01.07.2008, p. 263-270.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Chung, Hyun Cheol ; Kang, Won Ki ; Park, Sook Ryun ; Kim, Chul Soo ; Kim, Tae Yue ; Shin, Sang Won ; Park, Byung Joo ; Cha, Soo Jin ; Bang, Yung Jue. / Pemetrexed and cisplatin in patients with advanced gastric cancer : A Korean cancer study group multicenter phase II study. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 62, No. 2. pp. 263-270.
@article{edd5c24ce5e44fe79cb65bf7fca43ef4,
title = "Pemetrexed and cisplatin in patients with advanced gastric cancer: A Korean cancer study group multicenter phase II study",
abstract = "Background: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. Patients and methods: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. Results: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26{\%} (95{\%} CI, 14.6-40.3{\%}) and 15 (30{\%}) had stable disease. Median time to progression was 2.8 months (95{\%}CI, 2.2-4.4 months), and median overall survival was 6.6 months (95{\%} CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49{\%} of patients (25{\%} of cycles) and anorexia in 10{\%} of patients (4{\%} of cycles). Conclusion: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.",
keywords = "Advanced gastric cancer, Chemotherapy, Cisplatin, Pemetrexed, Phase II trial",
author = "Kim, {Yeul Hong} and Chung, {Hyun Cheol} and Kang, {Won Ki} and Park, {Sook Ryun} and Kim, {Chul Soo} and Kim, {Tae Yue} and Shin, {Sang Won} and Park, {Byung Joo} and Cha, {Soo Jin} and Bang, {Yung Jue}",
year = "2008",
month = "7",
day = "1",
doi = "10.1007/s00280-007-0600-y",
language = "English",
volume = "62",
pages = "263--270",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Pemetrexed and cisplatin in patients with advanced gastric cancer

T2 - A Korean cancer study group multicenter phase II study

AU - Kim, Yeul Hong

AU - Chung, Hyun Cheol

AU - Kang, Won Ki

AU - Park, Sook Ryun

AU - Kim, Chul Soo

AU - Kim, Tae Yue

AU - Shin, Sang Won

AU - Park, Byung Joo

AU - Cha, Soo Jin

AU - Bang, Yung Jue

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. Patients and methods: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. Results: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6-40.3%) and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2-4.4 months), and median overall survival was 6.6 months (95% CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles). Conclusion: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.

AB - Background: Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination in the treatment of AGC in Korean patients. Patients and methods: This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria. Results: Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6-40.3%) and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2-4.4 months), and median overall survival was 6.6 months (95% CI, 4.8-10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles). Conclusion: PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations and dose regimens are, therefore, warranted.

KW - Advanced gastric cancer

KW - Chemotherapy

KW - Cisplatin

KW - Pemetrexed

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=43949126887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43949126887&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0600-y

DO - 10.1007/s00280-007-0600-y

M3 - Article

VL - 62

SP - 263

EP - 270

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -